https://www.pharmaceutical-technology.com/data-insights/prt-3645-prelude-therapeutics-sarcomas-likelihood-of-approval/ 2024-12-30T16:50:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-3645-prelude-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-30T16:50:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-193-amgen-esophageal-cancer-likelihood-of-approval/ 2024-12-30T16:50:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sm-030-dermbiont-melasma-chlosma-likelihood-of-approval/ 2024-12-30T16:50:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-193-amgen-gastric-cancer-likelihood-of-approval/ 2024-12-30T16:50:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-193-amgen-glioma-likelihood-of-approval/ 2024-12-30T16:50:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/antionkoran-m-gene-surgery-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T16:50:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ela-026-electra-therapeutics-hemophagocytic-lymphohistiocytosis-likelihood-of-approval/ 2024-12-30T16:50:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/antionkoran-m-gene-surgery-penile-cancer-likelihood-of-approval/ 2024-12-30T16:50:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/antionkoran-m-gene-surgery-vulvar-cancer-likelihood-of-approval/ 2024-12-30T16:50:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/antionkoran-m-gene-surgery-solid-tumor-likelihood-of-approval/ 2024-12-30T16:49:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/antionkoran-m-gene-surgery-anal-cancer-likelihood-of-approval/ 2024-12-30T16:49:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/antionkoran-m-gene-surgery-cervical-cancer-likelihood-of-approval/ 2024-12-30T16:49:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/antionkoran-m-gene-surgery-melanoma-likelihood-of-approval/ 2024-12-30T16:49:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnt-517-jnana-therapeutics-phenylketonuria-pku-likelihood-of-approval/ 2024-12-30T16:49:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/antionkoran-m-gene-surgery-breast-cancer-likelihood-of-approval/ 2024-12-30T16:49:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/r3r-01-river-3-renal-alport-syndrome-likelihood-of-approval/ 2024-12-30T16:49:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enlicitide-decanoate-merck-atherosclerosis-likelihood-of-approval/ 2024-12-30T16:49:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afa-281-afasci-neuropathic-pain-neuralgia-likelihood-of-approval/ 2024-12-30T16:49:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/r3r-01-river-3-renal-focal-segmental-glomerulosclerosis-fsgs-likelihood-of-approval/ 2024-12-30T16:49:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/te-8105-immunwork-obesity-likelihood-of-approval/ 2024-12-30T16:49:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blm-07d1-systimmune-gastric-cancer-likelihood-of-approval/ 2024-12-30T16:49:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zx-4081-hangzhou-zenshine-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T16:49:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zx-4081-hangzhou-zenshine-pharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T16:49:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zx-4081-hangzhou-zenshine-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-12-30T16:49:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zx-4081-hangzhou-zenshine-pharmaceuticals-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T16:49:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zx-4081-hangzhou-zenshine-pharmaceuticals-colorectal-cancer-likelihood-of-approval/ 2024-12-30T16:49:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zx-4081-hangzhou-zenshine-pharmaceuticals-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T16:49:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zx-4081-hangzhou-zenshine-pharmaceuticals-breast-cancer-likelihood-of-approval/ 2024-12-30T16:48:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zx-4081-hangzhou-zenshine-pharmaceuticals-ovarian-cancer-likelihood-of-approval/ 2024-12-30T16:48:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2068-fusion-pharmaceuticals-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T16:48:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2068-fusion-pharmaceuticals-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-30T16:48:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2068-fusion-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-12-30T16:48:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2068-fusion-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T16:48:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icovamenib-biomea-fusion-solid-tumor-likelihood-of-approval/ 2024-12-30T16:48:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/csb-001-claris-biotherapeutics-limbal-stem-cell-deficiency-lscd-likelihood-of-approval/ 2024-12-30T16:48:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mh-004-minghui-pharmaceutical-shanghai-vitiligo-likelihood-of-approval/ 2024-12-30T16:48:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fgm-108-futuregen-biopharm-technology-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-30T16:48:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/my-004-createrna-science-and-technology-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-30T16:48:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/my-004-createrna-science-and-technology-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-30T16:48:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2858-chia-tai-tianqing-pharmaceutical-group-nasopharyngeal-cancer-likelihood-of-approval/ 2024-12-30T16:48:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/my-004-createrna-science-and-technology-psoriasis-likelihood-of-approval/ 2024-12-30T16:48:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iti-1284-intra-cellular-therapies-generalized-anxiety-disorder-gad-likelihood-of-approval/ 2024-12-30T16:48:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-jiangsu-hengrui-medicine-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T16:48:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvl-655-nuvalent-breast-cancer-likelihood-of-approval/ 2024-12-30T16:47:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvl-655-nuvalent-colorectal-cancer-likelihood-of-approval/ 2024-12-30T16:47:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wtx-330-werewolf-therapeutics-colorectal-cancer-likelihood-of-approval/ 2024-12-30T16:47:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-6236-revolution-medicines-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T16:47:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sw-682-springworks-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-30T16:47:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sw-682-springworks-therapeutics-malignant-mesothelioma-likelihood-of-approval/ 2024-12-30T16:47:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0025-huabo-biopharm-shanghai-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T16:47:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0025-huabo-biopharm-shanghai-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T16:47:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0025-huabo-biopharm-shanghai-endometrial-cancer-likelihood-of-approval/ 2024-12-30T16:47:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0025-huabo-biopharm-shanghai-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T16:47:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cpl-409116-celon-pharma-rheumatoid-arthritis-likelihood-of-approval/ 2024-12-30T16:47:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0025-huabo-biopharm-shanghai-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-30T16:47:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plerixafor-tacrolimus-medregen-spinal-cord-injury-likelihood-of-approval/ 2024-12-30T16:47:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plerixafor-tacrolimus-medregen-keloids-likelihood-of-approval/ 2024-12-30T16:47:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plerixafor-tacrolimus-medregen-diabetic-nephropathy-likelihood-of-approval/ 2024-12-30T16:47:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plerixafor-tacrolimus-medregen-inflammatory-bowel-disease-likelihood-of-approval/ 2024-12-30T16:47:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plerixafor-tacrolimus-medregen-traumatic-brain-injury-likelihood-of-approval/ 2024-12-30T16:46:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plerixafor-tacrolimus-medregen-acute-renal-failure-arf-acute-kidney-injury-likelihood-of-approval/ 2024-12-30T16:46:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2618-chia-tai-tianqing-pharmaceutical-group-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T16:46:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plerixafor-tacrolimus-medregen-transplant-rejection-likelihood-of-approval/ 2024-12-30T16:46:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hgi-001-shenzhen-hemogen-gene-biotechnology-beta-thalassaemia-likelihood-of-approval/ 2024-12-30T16:46:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2618-chia-tai-tianqing-pharmaceutical-group-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-30T16:46:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-3789-prelude-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-30T16:46:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-02-attralus-primary-systemic-amyloidosis-likelihood-of-approval/ 2024-12-30T16:46:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onureg-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-30T16:46:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-3789-prelude-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-30T16:46:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zifibancimig-f-hoffmann-la-roche-choroidal-neovascularization-likelihood-of-approval/ 2024-12-30T16:46:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zifibancimig-f-hoffmann-la-roche-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-12-30T16:46:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-15025-beigene-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-30T16:46:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-15025-beigene-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-30T16:46:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-15025-beigene-colorectal-cancer-likelihood-of-approval/ 2024-12-30T16:46:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-15025-beigene-cervical-cancer-likelihood-of-approval/ 2024-12-30T16:46:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/divarasib-genentech-usa-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-30T16:45:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/carenoprazan-hydrochloride-jiangsu-carephar-pharmaceutical-duodenal-ulcer-likelihood-of-approval/ 2024-12-30T16:45:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-30T16:45:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/gcc-4001-artiva-biotherapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-12-30T16:42:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-bms-opdivo-qvantig/ 2024-12-30T12:39:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/beigenes-tevimbra-approved-in-us-for-first-line-gastric-cancer-treatment/ 2024-12-30T10:42:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-12-30T16:42:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-12-29T18:16:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-12-29T18:16:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-follicular-lymphoma-likelihood-of-approval/ 2024-12-29T18:16:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-lupus-nephritis-likelihood-of-approval/ 2024-12-29T18:16:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T18:15:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-29T18:15:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-12-29T18:15:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-head-and-neck-cancer-likelihood-of-approval/ 2024-12-29T18:15:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelistotug-gsk-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-29T18:15:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-3454-chia-tai-tianqing-pharmaceutical-group-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T18:15:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rc-402-virocure-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2024-12-29T18:15:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rc-402-virocure-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-29T18:15:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/and-017-kind-pharmaceuticals-beta-thalassaemia-likelihood-of-approval/ 2024-12-29T18:15:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-albumin-bound-cspc-pharmaceutical-group-solid-tumor-likelihood-of-approval/ 2024-12-29T18:15:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-albumin-bound-cspc-pharmaceutical-group-gastric-cancer-likelihood-of-approval/ 2024-12-29T18:15:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-albumin-bound-cspc-pharmaceutical-group-prostate-cancer-likelihood-of-approval/ 2024-12-29T18:15:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bexicaserin-longboard-pharmaceuticals-developmental-disorders-likelihood-of-approval/ 2024-12-29T18:15:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bexicaserin-longboard-pharmaceuticals-epileptic-encephalopathy-likelihood-of-approval/ 2024-12-29T18:14:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-600-anaveon-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:14:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-600-anaveon-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-29T18:14:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-600-anaveon-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:14:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-600-anaveon-solid-tumor-likelihood-of-approval/ 2024-12-29T18:14:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-600-anaveon-melanoma-likelihood-of-approval/ 2024-12-29T18:14:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-031-antengene-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2024-12-29T18:14:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-031-antengene-liver-cancer-likelihood-of-approval/ 2024-12-29T18:14:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-031-antengene-ovarian-cancer-likelihood-of-approval/ 2024-12-29T18:14:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-031-antengene-lung-cancer-likelihood-of-approval/ 2024-12-29T18:14:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-031-antengene-breast-cancer-likelihood-of-approval/ 2024-12-29T18:14:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tofacitinib-citrate-twi-biotechnology-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-29T18:14:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hbm-7008-harbour-biomed-guangzhou-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-29T18:14:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stp-707-sirnaomics-solid-tumor-likelihood-of-approval/ 2024-12-29T18:13:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stp-707-sirnaomics-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T18:13:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stp-707-sirnaomics-colon-cancer-likelihood-of-approval/ 2024-12-29T18:13:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azvudine-henan-genuine-biotech-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-29T18:13:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azvudine-henan-genuine-biotech-colorectal-cancer-likelihood-of-approval/ 2024-12-29T18:13:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azvudine-henan-genuine-biotech-lung-cancer-likelihood-of-approval/ 2024-12-29T18:13:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:13:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/uc-mscs-wuhan-hamilton-bio-technology-osteoarthritis-likelihood-of-approval/ 2024-12-29T18:13:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/povetacicept-alpine-immune-sciences-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2024-12-29T18:13:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arthex-01-arthex-biotech-myotonic-dystrophy-likelihood-of-approval/ 2024-12-29T18:13:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgba-445-beigene-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:13:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mvd-1-eolo-pharma-obesity-likelihood-of-approval/ 2024-12-29T18:13:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-cedazuridine-taiho-oncology-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2024-12-29T18:13:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-cedazuridine-taiho-oncology-refractory-anemia-with-ringed-sideroblasts-likelihood-of-approval/ 2024-12-29T18:12:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-cedazuridine-taiho-oncology-refractory-anemia-with-excess-blasts-likelihood-of-approval/ 2024-12-29T18:12:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-cedazuridine-taiho-oncology-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-29T18:12:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mas-825-novartis-hidradenitis-suppurativa-likelihood-of-approval/ 2024-12-29T18:12:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapa-201-rapa-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-29T18:12:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapa-201-rapa-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-12-29T18:12:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azenosertib-zentalis-pharmaceuticals-peritoneal-cancer-likelihood-of-approval/ 2024-12-29T18:12:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azenosertib-zentalis-pharmaceuticals-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-29T18:12:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azenosertib-zentalis-pharmaceuticals-ovarian-cancer-likelihood-of-approval/ 2024-12-29T18:12:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-099280-incyte-gastrointestinal-tumor-likelihood-of-approval/ 2024-12-29T18:12:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-29T18:12:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-head-and-neck-carcinoma-likelihood-of-approval/ 2024-12-29T18:12:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-metastatic-uveal-melanoma-likelihood-of-approval/ 2024-12-29T18:12:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-12-29T18:11:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-12-29T18:11:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-acral-lentiginous-melanoma-likelihood-of-approval/ 2024-12-29T18:11:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-29T18:11:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-laryngeal-cancer-likelihood-of-approval/ 2024-12-29T18:11:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-hypopharyngeal-cancer-likelihood-of-approval/ 2024-12-29T18:11:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-esophageal-cancer-likelihood-of-approval/ 2024-12-29T18:11:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-solid-tumor-likelihood-of-approval/ 2024-12-29T18:11:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-12-29T18:11:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-gastric-cancer-likelihood-of-approval/ 2024-12-29T18:11:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tulisokibart-merck-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-12-29T18:11:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/purinostat-mesylate-chengdu-zenitar-biomedical-technology-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2024-12-29T18:11:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/purinostat-mesylate-chengdu-zenitar-biomedical-technology-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-12-29T18:11:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/purinostat-mesylate-chengdu-zenitar-biomedical-technology-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-12-29T18:11:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/myj-1633-immunisbio-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T18:10:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/indemakitug-elixiron-immunotherapeutics-vitiligo-likelihood-of-approval/ 2024-12-29T18:10:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-admscs-hope-biosciences-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval/ 2024-12-29T18:10:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-4685-ono-pharmaceutical-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-12-29T18:10:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-4685-ono-pharmaceutical-mycosis-fungoides-likelihood-of-approval/ 2024-12-29T18:10:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-4685-ono-pharmaceutical-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-12-29T18:10:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-4685-ono-pharmaceutical-sezary-syndrome-likelihood-of-approval/ 2024-12-29T18:10:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-4685-ono-pharmaceutical-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-12-29T18:10:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-4685-ono-pharmaceutical-t-cell-lymphomas-likelihood-of-approval/ 2024-12-29T18:10:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jbi-802-jubilant-therapeutics-neuroendocrine-tumors-likelihood-of-approval/ 2024-12-29T18:10:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jbi-802-jubilant-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:10:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jbi-802-jubilant-therapeutics-myeloproliferative-disorders-likelihood-of-approval/ 2024-12-29T18:10:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jbi-802-jubilant-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-29T18:10:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jbi-802-jubilant-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:09:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jbi-802-jubilant-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-29T18:09:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jbi-802-jubilant-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-29T18:09:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jbi-802-jubilant-therapeutics-prostate-cancer-likelihood-of-approval/ 2024-12-29T18:09:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evo-301-evommune-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-12-29T18:09:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evo-301-evommune-systemic-onset-juvenile-idiopathic-arthritis-still-disease-likelihood-of-approval/ 2024-12-29T18:09:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emfizatamab-systimmune-solid-tumor-likelihood-of-approval/ 2024-12-29T18:09:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zg-005-suzhou-zelgen-biopharmaceutical-neuroendocrine-carcinoma-likelihood-of-approval/ 2024-12-29T18:09:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zg-005-suzhou-zelgen-biopharmaceutical-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T18:09:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zg-005-suzhou-zelgen-biopharmaceutical-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-29T18:09:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dd-01-d-d-pharmatech-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-29T18:09:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cta-101-nanjing-bioheng-biotech-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T18:09:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemacabtagene-ansegedleucel-allogene-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T18:09:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbx-12-cybrexa-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:09:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-1505-schrodinger-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T18:08:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-1505-schrodinger-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T18:08:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-1505-schrodinger-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-29T18:08:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-1505-schrodinger-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-12-29T18:08:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-1505-schrodinger-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-12-29T18:08:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-1505-schrodinger-follicular-lymphoma-likelihood-of-approval/ 2024-12-29T18:08:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-1505-schrodinger-burkitt-lymphoma-likelihood-of-approval/ 2024-12-29T18:08:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dorocubicel-excellthera-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-29T18:08:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lesabelimab-dragonboat-biopharmaceutical-shanghai-endometrial-cancer-likelihood-of-approval/ 2024-12-29T18:08:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabometyx-exelixis-ureter-cancer-likelihood-of-approval/ 2024-12-29T18:08:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabometyx-exelixis-urethral-cancer-likelihood-of-approval/ 2024-12-29T18:08:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ata-100-atamyo-therapeutics-limb-girdle-muscular-dystrophy-likelihood-of-approval/ 2024-12-29T18:08:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazostinag-sodium-takeda-pharmaceutical-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-29T18:08:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazostinag-sodium-takeda-pharmaceutical-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-29T18:07:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazostinag-sodium-takeda-pharmaceutical-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:07:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tunlametinib-binjiang-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:07:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tunlametinib-binjiang-pharma-solid-tumor-likelihood-of-approval/ 2024-12-29T18:07:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tunlametinib-binjiang-pharma-metastatic-melanoma-likelihood-of-approval/ 2024-12-29T18:07:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linperlisib-shanghai-yingli-pharmaceutical-hematological-tumor-likelihood-of-approval/ 2024-12-29T18:07:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linperlisib-shanghai-yingli-pharmaceutical-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2024-12-29T18:07:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linperlisib-shanghai-yingli-pharmaceutical-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-12-29T18:07:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linperlisib-shanghai-yingli-pharmaceutical-follicular-lymphoma-likelihood-of-approval/ 2024-12-29T18:07:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ak-119-akaal-pharma-multiple-sclerosis-likelihood-of-approval/ 2024-12-29T18:07:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-1808-bioinvent-international-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-12-29T18:07:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-1808-bioinvent-international-t-cell-lymphomas-likelihood-of-approval/ 2024-12-29T18:07:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-1808-bioinvent-international-gastrointestinal-stromal-tumor-gist-likelihood-of-approval/ 2024-12-29T18:07:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-1808-bioinvent-international-melanoma-likelihood-of-approval/ 2024-12-29T18:06:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camonsertib-repare-therapeutics-melanoma-likelihood-of-approval/ 2024-12-29T18:06:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-29T18:06:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-neuroblastoma-likelihood-of-approval/ 2024-12-29T18:06:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-burkitt-lymphoma-likelihood-of-approval/ 2024-12-29T18:06:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-ewing-sarcoma-likelihood-of-approval/ 2024-12-29T18:06:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kd-025-nanjing-kaedi-biotech-medulloblastoma-likelihood-of-approval/ 2024-12-29T18:06:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kd-025-nanjing-kaedi-biotech-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T18:06:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kd-025-nanjing-kaedi-biotech-solid-tumor-likelihood-of-approval/ 2024-12-29T18:06:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kd-025-nanjing-kaedi-biotech-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-29T18:06:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zm-008-zumutor-biologics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-29T18:06:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zm-008-zumutor-biologics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-29T18:06:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zm-008-zumutor-biologics-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2024-12-29T18:06:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zm-008-zumutor-biologics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:06:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zm-008-zumutor-biologics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T18:05:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zm-008-zumutor-biologics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T18:05:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zm-008-zumutor-biologics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T18:05:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zm-008-zumutor-biologics-colorectal-cancer-likelihood-of-approval/ 2024-12-29T18:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zm-008-zumutor-biologics-prostate-cancer-likelihood-of-approval/ 2024-12-29T18:05:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zm-008-zumutor-biologics-ovarian-cancer-likelihood-of-approval/ 2024-12-29T18:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rulonilimab-shandong-new-time-pharmaceutical-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-12-29T18:05:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifenprodil-seyltx-chronic-cough-likelihood-of-approval/ 2024-12-29T18:05:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sunobinop-tosylate-imbrium-therapeutics-overactive-bladder-likelihood-of-approval/ 2024-12-29T18:05:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nizubaglustat-azafaros-gm1-gangliosidosis-beta-galactosidase-1-deficiency-likelihood-of-approval-2/ 2024-12-29T18:05:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-1-guangzhou-huajin-pharmaceutical-technology-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T18:05:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-1-guangzhou-huajin-pharmaceutical-technology-liver-cancer-likelihood-of-approval/ 2024-12-29T18:05:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-relatlimab-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-29T18:05:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-002-shanghai-miracogen-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T18:04:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-cspc-pharmaceutical-group-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-12-29T18:04:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mdi-2517-mdi-therapeutics-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/ 2024-12-29T18:04:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mdi-2517-mdi-therapeutics-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-12-29T18:04:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eik-1001-eikon-therapeutics-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T18:04:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligufalimab-akeso-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-12-29T18:04:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligufalimab-akeso-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-29T18:04:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligufalimab-akeso-laryngeal-cancer-likelihood-of-approval/ 2024-12-29T18:04:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligufalimab-akeso-hypopharyngeal-cancer-likelihood-of-approval/ 2024-12-29T18:04:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligufalimab-akeso-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-29T18:04:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligufalimab-akeso-cervical-cancer-likelihood-of-approval/ 2024-12-29T18:04:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligufalimab-akeso-colorectal-cancer-likelihood-of-approval/ 2024-12-29T18:04:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-0306-immuneonco-biopharmaceuticals-shanghai-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T18:04:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-1291583-boehringer-ingelheim-international-bronchiectasis-likelihood-of-approval/ 2024-12-29T18:03:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/descartes-08-cartesian-therapeutics-myasthenia-gravis-likelihood-of-approval/ 2024-12-29T18:03:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relmacabtagene-autoleucel-bristol-myers-squibb-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-12-29T18:03:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexmedetomidine-bioxcel-therapeutics-opium-withdrawal-syndrome-likelihood-of-approval/ 2024-12-29T18:03:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amesanar-rheacell-venous-leg-ulcers-crural-ulcer-likelihood-of-approval/ 2024-12-29T18:03:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-secondary-cns-lymphoma-likelihood-of-approval/ 2024-12-29T18:03:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-primary-cns-lymphoma-likelihood-of-approval/ 2024-12-29T18:03:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vixarelimab-genentech-usa-ulcerative-colitis-likelihood-of-approval/ 2024-12-29T18:03:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-29T18:03:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hmpl-306-hutchison-medipharma-hematological-tumor-likelihood-of-approval/ 2024-12-29T18:03:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-mabxience-holding-post-menopausal-osteoporosis-likelihood-of-approval/ 2024-12-29T18:03:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/merck-program2-merck-inflammation-likelihood-of-approval/ 2024-12-29T18:03:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/can-3110-candel-therapeutics-oligodendroglioma-likelihood-of-approval/ 2024-12-29T18:03:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hmbd-001-hummingbird-bioscience-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-29T18:02:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hmbd-001-hummingbird-bioscience-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-29T18:02:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hmbd-001-hummingbird-bioscience-gastric-cancer-likelihood-of-approval/ 2024-12-29T18:02:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adebrelimab-jiangsu-hengrui-medicine-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-29T18:02:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tp-317-thetis-pharmaceuticals-inflammatory-bowel-disease-likelihood-of-approval/ 2024-12-29T18:02:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hp-501-sr-hinova-pharmaceuticals-gouty-arthritis-gout-likelihood-of-approval/ 2024-12-29T18:02:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hp-501-sr-hinova-pharmaceuticals-hyperuricemia-likelihood-of-approval/ 2024-12-29T18:02:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zelenectide-pevedotin-bicycle-therapeutics-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-12-29T18:02:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-curateq-biologics-peritoneal-cancer-likelihood-of-approval/ 2024-12-29T18:02:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-curateq-biologics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-29T18:02:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-curateq-biologics-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-12-29T18:02:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-curateq-biologics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T18:02:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-curateq-biologics-cervical-cancer-likelihood-of-approval/ 2024-12-29T18:02:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-curateq-biologics-ovarian-cancer-likelihood-of-approval/ 2024-12-29T18:01:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-curateq-biologics-breast-cancer-likelihood-of-approval/ 2024-12-29T18:01:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-4578-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-29T18:01:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deflexifol-fivephusion-ependymoma-likelihood-of-approval/ 2024-12-29T18:01:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pep-07-sentinel-oncology-solid-tumor-likelihood-of-approval/ 2024-12-29T18:01:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trgft-201-orca-biosystems-blood-cancer-likelihood-of-approval/ 2024-12-29T18:01:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ng-350a-akamis-bio-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-12-29T18:01:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abl-105-abl-bio-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T18:01:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zegocractin-calcimedica-acute-renal-failure-arf-acute-kidney-injury-likelihood-of-approval/ 2024-12-29T18:01:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acetylcysteine-zidrimer-orpheris-parkinson-s-disease-likelihood-of-approval/ 2024-12-29T18:01:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etd-001-enterprise-therapeutics-cystic-fibrosis-likelihood-of-approval/ 2024-12-29T18:01:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pirtobrutinib-eli-lilly-and-co-b-cell-chronic-lymphocytic-leukemia-likelihood-of-approval/ 2024-12-29T18:01:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olverembatinib-ascentage-pharma-group-international-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-12-29T18:01:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-primary-systemic-amyloidosis-likelihood-of-approval/ 2024-12-29T18:00:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sugemalimab-cstone-pharmaceuticals-natural-killer-cell-lymphomas-likelihood-of-approval/ 2024-12-29T18:00:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ascorbic-acid-renovion-chronic-bronchitis-likelihood-of-approval/ 2024-12-29T18:00:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obi-3424-obi-pharma-salivary-gland-cancer-likelihood-of-approval/ 2024-12-29T18:00:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obi-3424-obi-pharma-breast-cancer-likelihood-of-approval/ 2024-12-29T18:00:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/art-4215-artios-pharma-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T18:00:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/art-4215-artios-pharma-solid-tumor-likelihood-of-approval/ 2024-12-29T18:00:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esepapogene-zalarnarepvec-hookipa-pharma-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-29T18:00:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/domvanalimab-arcus-biosciences-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T18:00:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/domvanalimab-arcus-biosciences-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T18:00:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pax-1-komipharm-international-non-small-cell-lung-carcinoma-likelihood-of-approval/ 2024-12-29T18:00:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-rectal-cancer-likelihood-of-approval/ 2024-12-29T18:00:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lipidrescue-resq-pharma-drug-toxicity-likelihood-of-approval/ 2024-12-29T18:00:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pivekimab-sunirine-immunogen-blood-cancer-likelihood-of-approval/ 2024-12-29T17:59:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T17:59:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-29T17:59:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/estradiol-acetate-viramal-menopausal-disorders-likelihood-of-approval/ 2024-12-29T17:59:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ent-01-enterin-constipation-likelihood-of-approval/ 2024-12-29T17:59:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cntx-6970-centrexion-therapeutics-osteoarthritis-pain-likelihood-of-approval/ 2024-12-29T17:59:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voyager-v1-vyriad-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:59:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-angiosarcoma-likelihood-of-approval/ 2024-12-29T17:59:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-nonmelanomatous-skin-cancer-likelihood-of-approval/ 2024-12-29T17:59:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-esophageal-cancer-likelihood-of-approval/ 2024-12-29T17:59:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:59:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-29T17:59:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-bladder-cancer-likelihood-of-approval/ 2024-12-29T17:59:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:58:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-023-les-laboratoires-servier-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-29T17:58:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-023-les-laboratoires-servier-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-12-29T17:58:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-023-les-laboratoires-servier-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2024-12-29T17:58:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-023-les-laboratoires-servier-gallbladder-cancer-likelihood-of-approval/ 2024-12-29T17:58:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-023-les-laboratoires-servier-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T17:58:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-023-les-laboratoires-servier-solid-tumor-likelihood-of-approval/ 2024-12-29T17:58:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2223-chia-tai-tianqing-pharmaceutical-group-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-29T17:58:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2223-chia-tai-tianqing-pharmaceutical-group-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-12-29T17:58:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2223-chia-tai-tianqing-pharmaceutical-group-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2024-12-29T17:58:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2223-chia-tai-tianqing-pharmaceutical-group-gallbladder-cancer-likelihood-of-approval/ 2024-12-29T17:58:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-021-les-laboratoires-servier-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-29T17:58:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-021-les-laboratoires-servier-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-12-29T17:58:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-021-les-laboratoires-servier-metastatic-cancer-likelihood-of-approval/ 2024-12-29T17:57:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-021-les-laboratoires-servier-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2024-12-29T17:57:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-021-les-laboratoires-servier-gallbladder-cancer-likelihood-of-approval/ 2024-12-29T17:57:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-021-les-laboratoires-servier-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T17:57:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-021-les-laboratoires-servier-solid-tumor-likelihood-of-approval/ 2024-12-29T17:57:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T17:57:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-29T17:57:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-triple-negative-breast-cancer-tnbc-likelihood-of-approval-2/ 2024-12-29T17:57:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-29T17:57:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-starlight-therapeutics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:57:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-melanoma-likelihood-of-approval-2/ 2024-12-29T17:57:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalpiciclib-jiangsu-hengrui-medicine-hormone-sensitive-prostate-cancer-likelihood-of-approval/ 2024-12-29T17:57:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linvoseltamab-regeneron-pharmaceuticals-primary-systemic-amyloidosis-likelihood-of-approval/ 2024-12-29T17:57:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemcitabine-johnson-johnson-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:56:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/var-200-zyversa-therapeutics-focal-segmental-glomerulosclerosis-fsgs-likelihood-of-approval/ 2024-12-29T17:56:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-adc-therapeutics-follicular-lymphoma-likelihood-of-approval/ 2024-12-29T17:56:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-adc-therapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2024-12-29T17:56:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-leptomeningeal-disease-neoplastic-meningitis-leptomeningeal-carcinomatosis-likelihood-of-approval/ 2024-12-29T17:56:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zen-3694-zenith-epigenetics-nut-midline-carcinoma-nmc-or-nuclear-protein-in-testis-midline-carcinoma-likelihood-of-approval/ 2024-12-29T17:56:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zen-3694-zenith-epigenetics-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:56:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zen-3694-zenith-epigenetics-peritoneal-cancer-likelihood-of-approval/ 2024-12-29T17:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zen-3694-zenith-epigenetics-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-29T17:56:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zen-3694-zenith-epigenetics-t-cell-lymphomas-likelihood-of-approval/ 2024-12-29T17:56:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zen-3694-zenith-epigenetics-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T17:56:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zen-3694-zenith-epigenetics-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:56:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ciforadenant-corvus-pharmaceuticals-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:56:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fuzuloparib-jiangsu-hengrui-medicine-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-29T17:55:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fuzuloparib-jiangsu-hengrui-medicine-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T17:55:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retifanlimab-incyte-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:55:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retifanlimab-incyte-sarcomas-likelihood-of-approval/ 2024-12-29T17:55:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retifanlimab-incyte-cervical-cancer-likelihood-of-approval/ 2024-12-29T17:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrx-8-micurx-pharmaceuticals-pseudomonas-aeruginosa-infections-likelihood-of-approval/ 2024-12-29T17:55:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrx-8-micurx-pharmaceuticals-escherichia-coli-infections-likelihood-of-approval/ 2024-12-29T17:55:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrx-8-micurx-pharmaceuticals-acinetobacter-infections-likelihood-of-approval/ 2024-12-29T17:55:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T17:55:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camrelizumab-jiangsu-hengrui-medicine-follicular-lymphoma-likelihood-of-approval/ 2024-12-29T17:55:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camrelizumab-elevar-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-29T17:54:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/doxorubicin-innomedica-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:54:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/doxorubicin-innomedica-breast-cancer-likelihood-of-approval/ 2024-12-29T17:53:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omtx-705-oncomatryx-biopharma-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-29T17:52:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mankind-innovent-sintilimab-commercialisation/ 2024-12-27T10:29:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eisbach-bio-positions-hrd-targeting-therapy-to-supplant-parp-inhibitors/ 2024-12-24T19:54:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stemvacs-v-res-nova-bio-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-21T17:03:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lidocaine-medrx-postherpetic-neuralgia-likelihood-of-approval/ 2025-01-21T17:01:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kgyy-15-op-t-mune-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2025-01-21T17:01:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tricaprilin-cerecin-infantile-spasm-west-syndrome-likelihood-of-approval/ 2025-01-21T17:00:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-gd2-for-oncology-bristol-myers-squibb-osteosarcoma-likelihood-of-approval/ 2025-01-21T17:00:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-gd2-for-oncology-bristol-myers-squibb-sarcomas-likelihood-of-approval/ 2025-01-21T17:00:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelivaptan-hmnc-major-depressive-disorder-likelihood-of-approval/ 2025-01-21T16:59:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/darigabat-cerevel-therapeutics-seizures-likelihood-of-approval/ 2025-01-21T16:59:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allergen-for-grass-pollen-allergy-roxall-medizin-grass-pollen-allergy-likelihood-of-approval/ 2025-01-21T16:59:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immune-globulin-human-grifols-tachycardia-tachyarrhythmias-likelihood-of-approval/ 2025-01-21T16:58:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prexigebersen-bio-path-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T16:57:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prexigebersen-bio-path-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T16:57:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prexigebersen-bio-path-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-21T16:57:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cr-4056-rottapharm-biotech-osteoarthritis-pain-likelihood-of-approval/ 2025-01-21T16:56:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cg-0255-shanghai-curegene-pharmaceutical-acute-coronary-syndrome-likelihood-of-approval/ 2025-01-21T16:56:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cg-0255-shanghai-curegene-pharmaceutical-ischemic-stroke-likelihood-of-approval/ 2025-01-21T16:56:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctecells-cte-biologics-chronic-traumatic-encephalopathy-cte-likelihood-of-approval/ 2025-01-21T16:56:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cg-0255-shanghai-curegene-pharmaceutical-myocardial-infarction-likelihood-of-approval/ 2025-01-21T16:56:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rioderm-002-rion-radiation-injury-likelihood-of-approval/ 2025-01-21T16:56:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3971297-eli-lilly-and-co-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2025-01-21T16:55:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-1163-astrazeneca-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-21T16:55:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07976016-pfizer-obesity-likelihood-of-approval/ 2025-01-21T16:55:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abp-745-jiangsu-atom-bioscience-and-pharmaceutical-gouty-arthritis-gout-likelihood-of-approval/ 2025-01-21T16:55:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6382-f-hoffmann-la-roche-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-21T16:55:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ksp-1007-meropenem-sumitomo-pharma-hospital-acquired-pneumonia-hap-likelihood-of-approval/ 2025-01-21T16:54:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3972406-eli-lilly-and-co-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2025-01-21T16:54:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ksp-1007-meropenem-sumitomo-pharma-ventilator-associated-pneumonia-vap-likelihood-of-approval/ 2025-01-21T16:54:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvg-2089-nuvig-therapeutics-bullous-pemphigoid-likelihood-of-approval/ 2025-01-21T16:54:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvg-2089-nuvig-therapeutics-chronic-inflammation-likelihood-of-approval/ 2025-01-21T16:54:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-006-ascentawits-pharmaceuticals-breast-cancer-likelihood-of-approval/ 2025-01-21T16:54:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-006-ascentawits-pharmaceuticals-ovarian-cancer-likelihood-of-approval/ 2025-01-21T16:54:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tuberculosis-vaccine-1-chengdu-keen-biotechnology-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2025-01-21T16:53:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spl-028-cybin-generalized-anxiety-disorder-gad-likelihood-of-approval/ 2025-01-21T16:53:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caffeine-naproxen-sodium-bayer-post-operative-pain-likelihood-of-approval/ 2025-01-21T16:52:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-6434-novo-nordisk-hypercholesterolemia-likelihood-of-approval/ 2025-01-21T16:52:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/t-03-treamid-therapeutics-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-21T16:52:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trientine-hydrochloride-innolife-systolic-heart-failure-likelihood-of-approval-2/ 2025-01-21T16:52:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lidocaine-orexa-postoperative-ileus-likelihood-of-approval/ 2025-01-21T16:52:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/trientine-hydrochloride-innolife-systolic-heart-failure-likelihood-of-approval/ 2024-12-26T18:14:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-daiichi-sankyo-lung-cancer/ 2025-01-07T09:00:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/excellence-in-focus/iff-pharma-solutions-innovation-sustainability-angela-strzelecki/ 2025-05-05T12:05:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nb-4746-nura-bio-amyotrophic-lateral-sclerosis-likelihood-of-approval-2/ 2025-01-20T16:15:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/actus-101-asklepios-biopharmaceutical-pompe-disease-likelihood-of-approval-2/ 2025-01-20T02:16:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gamma-pn-gpn-vaccines-streptococcal-pneumonia-likelihood-of-approval-2/ 2025-01-20T02:15:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apraglutide-ironwood-pharmaceuticals-short-bowel-syndrome-likelihood-of-approval-2/ 2025-01-20T02:15:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aroc-3-arrowhead-pharmaceuticals-iga-nephropathy-berger-s-disease-likelihood-of-approval-2/ 2025-01-20T02:12:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exo-cd24-nano24med-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-19T18:27:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosravuconazole-eisai-tinea-pedis-athlete-foot-likelihood-of-approval/ 2025-01-19T18:24:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexamethasone-sodium-phosphate-sr-taiwan-liposome-osteoarthritis-pain-likelihood-of-approval-2/ 2025-01-19T18:22:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glufosfamide-eleison-pharmaceuticals-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval-2/ 2025-01-19T18:20:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vmt-01-perspective-therapeutics-metastatic-melanoma-likelihood-of-approval/ 2025-01-19T18:20:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hydrocodone-ir-elysium-therapeutics-opium-opioid-addiction-likelihood-of-approval-2/ 2025-01-19T18:20:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snk-396-synerk-lipid-disorders-likelihood-of-approval-2/ 2025-01-19T18:19:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/resiquimod-surge-therapeutics-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval-2/ 2025-01-19T18:18:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coya-301-coya-therapeutics-alzheimer-s-disease-likelihood-of-approval-2/ 2025-01-19T18:18:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hcp-1803-hanmi-pharmaceuticals-idiopathic-essential-hypertension-likelihood-of-approval-2/ 2025-01-19T18:17:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aut-00201-autifony-therapeutics-ataxia-likelihood-of-approval-2/ 2025-01-19T18:16:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aut-00201-autifony-therapeutics-myoclonic-seizure-likelihood-of-approval-2/ 2025-01-19T18:16:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vp-001-pyc-therapeutics-retinitis-pigmentosa-retinitis-likelihood-of-approval-2/ 2025-01-19T18:16:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tara-002-protara-therapeutics-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval-2/ 2025-01-19T18:16:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-309309-shionogi-obesity-likelihood-of-approval-2/ 2025-01-19T18:15:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olx-101a-olix-pharmaceuticals-hypertrophic-scars-likelihood-of-approval-2/ 2025-01-19T18:12:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-8630-astrazeneca-asthma-likelihood-of-approval-2/ 2025-01-19T18:06:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bx-004-biomx-resistant-pseudomonas-aeruginosa-infections-likelihood-of-approval-2/ 2025-01-19T18:03:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ak-otof-akouos-acute-sensorineural-hearing-loss-likelihood-of-approval-2/ 2025-01-19T17:50:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caficrestat-applied-therapeutics-cardiomyopathy-likelihood-of-approval-2/ 2025-01-19T17:50:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ciclopirox-atlas-molecular-pharma-porphyria-erythropoietic-protoporphyri-likelihood-of-approval-2/ 2025-01-19T17:50:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vesigel-urogen-pharma-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval-2/ 2025-01-19T17:49:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vidofludimus-calcium-immunic-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval-2/ 2025-01-19T17:48:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zelpultide-alfa-airway-therapeutics-bronchopulmonary-dysplasia-likelihood-of-approval-2/ 2025-01-19T17:44:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lufepirsen-amber-ophthalmics-persistent-corneal-epithelial-defects-likelihood-of-approval-2/ 2025-01-19T17:24:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizanlizumab-novartis-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval-2/ 2025-01-19T17:24:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pridopidine-hydrochloride-prilenia-therapeutics-development-huntington-disease-likelihood-of-approval-2/ 2025-01-19T17:24:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-samsung-bioepis-post-menopausal-osteoporosis-likelihood-of-approval-2/ 2025-01-19T16:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gh-002-gh-research-treatment-resistant-depression-likelihood-of-approval-2/ 2025-01-19T16:57:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bx-004-biomx-cystic-fibrosis-likelihood-of-approval-2/ 2025-01-19T16:56:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rec-163964-recursion-pharmaceuticals-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval-2/ 2025-01-19T16:55:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ext-608-extend-biosciences-hypoparathyroidism-likelihood-of-approval-2/ 2025-01-19T16:52:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sibeprenlimab-visterra-iga-nephropathy-berger-s-disease-likelihood-of-approval-2/ 2025-01-19T16:51:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acoltremon-alcon-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2025-01-19T16:51:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-06425090-pfizer-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval-2/ 2025-01-19T16:51:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/terbinafine-hydrochloride-moberg-pharma-onychomycosis-tinea-unguium-likelihood-of-approval-2/ 2025-01-19T16:44:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexmethylphenidate-hydrochloride-cingulate-attention-deficit-hyperactivity-disorder-adhd-likelihood-of-approval-2/ 2025-01-19T16:44:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizanlizumab-novartis-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval-2/ 2025-01-19T16:43:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quisovalimab-avalo-therapeutics-asthma-likelihood-of-approval-2/ 2025-01-19T16:42:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/csti-500-consynance-therapeutics-prader-willi-syndrome-pws-likelihood-of-approval-2/ 2025-01-19T16:41:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizanlizumab-novartis-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval-2/ 2025-01-19T16:41:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/samelisant-suven-life-sciences-narcolepsy-likelihood-of-approval-2/ 2025-01-19T16:41:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizanlizumab-novartis-myelofibrosis-likelihood-of-approval-2/ 2025-01-19T16:41:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fresolimumab-sanofi-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2025-01-19T16:39:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/xbiotech-halts-all-rheumatology-research-after-missing-phase-ii-endpoints/ 2024-12-24T13:51:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gemmabio-raises-34m-to-advance-gene-therapy-programmes/ 2024-12-24T13:01:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-gets-the-green-light-for-once-daily-haemophilia-drug-following-setbacks/ 2024-12-24T11:12:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rapt-jemincare-antibody-agreement/ 2024-12-24T10:50:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-tagrisso-ec-nsclc/ 2024-12-24T08:48:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-lillys-obesity-med-zepbound-to-treat-obstructive-sleep-apnoea/ 2024-12-23T13:22:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sk-bioscience-sanofi-pneumococcal/ 2024-12-23T12:35:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/investors-optimistic-about-continued-biotech-and-medtech-ipo-resurgence-in-2025/ 2024-12-23T13:40:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vertex-secures-two-fda-wins-for-cystic-fibrosis-both-with-boxed-warnings/ 2024-12-23T11:39:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lillys-uk-life-sciences-investment-a-pivotal-moment-says-analyst/ 2024-12-23T11:32:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-colorectal-combo-fda/ 2024-12-23T10:38:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-ionis-tryngolza-fcs/ 2024-12-20T14:23:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-takes-a-hit-as-cagrisema-underperforms-in-weight-loss/ 2024-12-20T15:25:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-confirms-end-of-eli-lillys-tirzepatide-shortage-after-re-evaluation/ 2024-12-20T13:27:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/uk-pharma-high-vpag-payback-rate-in-2025/ 2024-12-20T11:59:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/palleon-henlius-autoimmune-therapy/ 2024-12-20T10:23:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astellas-sangamo-capsid-neurological/ 2024-12-20T08:37:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/magazine-us-reproductive-laws-could-limit-women-participation-in-clinical-trials/ 2024-12-19T16:34:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vertex-stock-hurt-pain-trial-similar-placebo/ 2024-12-19T16:57:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mesoblast-ryoncil-sr-agvhd/ 2025-01-08T10:33:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msd-makes-obesity-play-in-up-to-2bn-deal-for-hansohs-glp-1ra-asset/ 2024-12-19T14:19:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bioage-novartis-targets-ageing/ 2024-12-19T09:46:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-holdings-catalent-16-5bn/ 2024-12-19T08:49:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pharmas-data-and-analytics-market-forecast-to-reach-to-2-1bn-by-2028/ 2024-12-18T16:36:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/healthcare-sector-industrial-refrigeration-methods-reduce-emissions/ 2024-12-18T16:10:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abera-orexo-vaccine/ 2024-12-18T14:35:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/petrovax-announces-positive-results-from-long-cov-iii-21-trial-of-longidaza-for-long-term-pulmonary-sequelae-of-covid-19/ 2024-12-18T15:46:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/oncology-rd-emerging-therapies-and-new-challenges/ 2025-08-04T12:59:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-targets-more-online-vendors-selling-unapproved-glp-1ra-products/ 2024-12-18T11:36:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-terray-molecule-therapies/ 2024-12-18T10:58:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-eva-insulin-injection/ 2024-12-18T08:38:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-invests-1-2bn-in-new-denmark-facility/ 2024-12-17T15:46:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/biotech-bounces-back-venture-funding/ 2024-12-17T15:26:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nmpa-msd-keytruda-nsclc/ 2024-12-17T14:40:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bavarian-nordic-mpox-sii/ 2024-12-17T09:32:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/cts-europe-2024-keep-the-burden-of-trials-away-from-patients-say-experts/ 2024-12-17T10:57:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-lung-cancer-prime/ 2024-12-18T09:47:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/adcs-breach-barriers-to-become-mainstream-cancer-treatment/ 2024-12-18T09:43:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-nemluvio-atopic-dermatitis/ 2024-12-16T14:59:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-future-of-third-party-logistics-in-an-evolving-biopharmaceutical-world/ 2024-12-17T13:04:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/reprieve-for-wuxi-as-biosecure-vote-likely-pushed-to-2025/ 2025-01-03T21:25:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/small-cell-lung-cancer-navigating-the-global-clinical-trial-landscape/ 2024-12-17T14:37:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents/ 2024-12-16T11:32:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/denmark-hta-evolution/ 2024-12-16T11:14:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chmp-lilly-crohns-therapy/ 2024-12-16T10:06:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-acquires-nimble-200m/ 2024-12-16T08:03:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1076986-neurocrine-biosciences-net-present-value/ 2024-12-15T16:54:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibuzatrelvir-pfizer-net-present-value/ 2024-12-15T16:54:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-6234-astrazeneca-net-present-value/ 2024-12-15T16:53:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ryz-101-bristol-myers-squibb-net-present-value/ 2024-12-15T16:53:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sipavibart-astrazeneca-net-present-value/ 2024-12-15T16:53:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eloralintide-eli-lilly-and-co-net-present-value/ 2024-12-15T16:52:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amycretin-novo-nordisk-net-present-value/ 2024-12-15T16:52:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agomelatine-alto-neuroscience-net-present-value/ 2024-12-15T16:52:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3541860-eli-lilly-and-co-net-present-value/ 2024-12-15T16:52:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enlicitide-decanoate-merck-net-present-value/ 2024-12-15T16:51:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hs-20093-gsk-net-present-value/ 2024-12-15T16:51:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hs-20089-gsk-net-present-value/ 2024-12-15T16:51:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-359-prime-medicine-net-present-value/ 2024-12-15T16:50:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esk-001-alumis-net-present-value/ 2024-12-15T16:50:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivxa-12-astrazeneca-net-present-value/ 2024-12-15T16:50:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-1184-genmab-net-present-value/ 2024-12-15T16:50:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-1-104-immuneering-net-present-value/ 2024-12-15T16:49:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efzimfotase-alfa-astrazeneca-net-present-value/ 2024-12-15T16:49:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-101-tscan-therapeutics-net-present-value/ 2024-12-15T16:49:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balcinrenone-dapagliflozin-astrazeneca-net-present-value/ 2024-12-15T16:48:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulefnersen-sodium-ionis-pharmaceuticals-net-present-value/ 2024-12-15T16:48:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-net-present-value/ 2024-12-15T16:48:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sigvotatug-vedotin-pfizer-net-present-value/ 2024-12-15T16:47:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cibotercept-keros-therapeutics-net-present-value/ 2024-12-15T16:47:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutetium-177lu-zadavotide-quraxetan-lantheus-net-present-value/ 2024-12-15T16:47:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-9805-revolution-medicines-net-present-value/ 2024-12-15T16:47:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ntla-2002-intellia-therapeutics-net-present-value/ 2024-12-15T16:46:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duvakitug-sanofi-net-present-value/ 2024-12-15T16:46:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apsa-02-armata-pharmaceuticals-net-present-value/ 2024-12-15T16:30:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-388-roche-net-present-value/ 2024-12-15T16:30:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0120-astrazeneca-net-present-value/ 2024-12-15T16:30:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sudocetaxel-zendusortide-theratechnologies-net-present-value/ 2024-12-15T16:29:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/givastomig-i-mab-net-present-value/ 2024-12-15T16:29:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dnl-343-denali-therapeutics-net-present-value/ 2024-12-15T16:29:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-100-tscan-therapeutics-net-present-value/ 2024-12-15T16:28:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-1-cardiol-therapeutics-net-present-value/ 2024-12-15T16:28:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-organon-co-net-present-value/ 2024-12-15T16:28:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brogidirsen-nippon-shinyaku-net-present-value/ 2024-12-15T16:28:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eneboparatide-astrazeneca-net-present-value/ 2024-12-15T16:27:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/appa-02-armata-pharmaceuticals-net-present-value/ 2024-12-15T16:27:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selvigaltin-galecto-net-present-value/ 2024-12-15T16:27:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arlocabtagene-autoleucel-bristol-myers-squibb-net-present-value/ 2024-12-15T16:26:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6641-roche-net-present-value/ 2024-12-15T16:26:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ata-3219-atara-biotherapeutics-net-present-value/ 2024-12-15T16:26:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vepdegestrant-arvinas-net-present-value/ 2024-12-15T16:25:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-3810109-gsk-net-present-value/ 2024-12-15T16:25:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vanzacaftor-deutivacaftor-tezacaftor-vertex-pharmaceuticals-net-present-value/ 2024-12-15T16:25:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zipalertinib-otsuka-net-present-value/ 2024-12-15T16:25:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexborneol-edaravone-simcere-pharmaceutical-group-net-present-value/ 2024-12-15T16:24:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-3858279-gsk-net-present-value/ 2024-12-15T16:24:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986446-bristol-myers-squibb-net-present-value/ 2024-12-15T16:24:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-471-compass-pathways-net-present-value/ 2024-12-15T16:23:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/descartes-08-cartesian-therapeutics-net-present-value/ 2024-12-15T16:23:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilganersen-sodium-ionis-pharmaceuticals-net-present-value/ 2024-12-15T16:23:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meloxicam-rizatriptan-axsome-therapeutics-net-present-value/ 2024-12-15T16:22:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danavorexton-takeda-pharmaceutical-net-present-value/ 2024-12-15T16:22:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/farletuzumab-ecteribulin-eisai-net-present-value/ 2024-12-15T16:22:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/srp-5051-sarepta-therapeutics-net-present-value/ 2024-12-15T16:22:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atumelnant-crinetics-pharmaceuticals-net-present-value/ 2024-12-15T16:21:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ptc-518-ptc-therapeutics-net-present-value/ 2024-12-15T16:21:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iti-333-intra-cellular-therapies-net-present-value/ 2024-12-15T16:21:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abl-001-compass-pathways-net-present-value/ 2024-12-15T16:20:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nidlegy-philogen-net-present-value/ 2024-12-15T16:20:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/doxecitine-doxribtimine-ucb-net-present-value/ 2024-12-15T16:20:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apinocaltamide-neurocrine-biosciences-net-present-value/ 2024-12-15T16:16:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-4157-merck-net-present-value/ 2024-12-15T16:14:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nexiguran-ziclumeran-intellia-therapeutics-net-present-value/ 2024-12-15T16:13:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mazisotine-eli-lilly-and-co-net-present-value/ 2024-12-15T16:13:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-net-present-value/ 2024-12-15T16:13:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plamotamab-xencor-net-present-value/ 2024-12-15T16:13:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pertuzumab-biosimilar-organon-co-net-present-value/ 2024-12-15T16:12:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bezuclastinib-cogent-biosciences-net-present-value/ 2024-12-15T16:12:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vx-880-vertex-pharmaceuticals-net-present-value/ 2024-12-15T16:12:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belatacept-biosimilar-alphamab-oncology-net-present-value/ 2024-12-15T16:11:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cibisatamab-roche-net-present-value/ 2024-12-15T16:11:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alxn-2220-astrazeneca-net-present-value/ 2024-12-15T16:09:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/firicabtagene-autoleucel-cargo-therapeutics-net-present-value/ 2024-12-15T16:09:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rusfertide-acetate-takeda-pharmaceutical-net-present-value/ 2024-12-15T16:08:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vimseltinib-ono-pharmaceutical-net-present-value/ 2024-12-15T16:08:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-102-immunome-net-present-value/ 2024-12-15T16:08:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camlipixant-gsk-net-present-value/ 2024-12-15T16:03:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pelabresib-novartis-net-present-value/ 2024-12-15T16:03:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iadademstat-oryzon-genomics-net-present-value/ 2024-12-15T16:03:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volixibat-potassium-mirum-pharmaceuticals-net-present-value/ 2024-12-15T16:03:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alks-2680-alkermes-net-present-value/ 2024-12-15T16:02:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cendakimab-bristol-myers-squibb-net-present-value/ 2024-12-15T16:02:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bepirovirsen-sodium-gsk-net-present-value/ 2024-12-15T16:02:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efruxifermin-akero-therapeutics-net-present-value/ 2024-12-15T16:01:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/birtamimab-prothena-corp-net-present-value/ 2024-12-15T16:01:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sepetaprost-santen-pharmaceutical-net-present-value/ 2024-12-15T16:01:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iberdomide-hydrochloride-bristol-myers-squibb-net-present-value/ 2024-12-15T16:00:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bitopertin-disc-medicine-net-present-value/ 2024-12-15T16:00:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenrispodun-phosphate-intra-cellular-therapies-net-present-value/ 2024-12-15T16:00:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aav-gad-meiragtx-net-present-value/ 2024-12-15T16:00:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adakitug-bristol-myers-squibb-net-present-value/ 2024-12-15T15:59:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acimtamig-affimed-net-present-value/ 2024-12-15T15:59:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cretostimogene-grenadenorepvec-cg-oncology-net-present-value/ 2024-12-15T15:59:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veligrotug-viridian-therapeutics-net-present-value/ 2024-12-15T15:58:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alprazolam-ucb-net-present-value/ 2024-12-15T15:58:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-net-present-value/ 2024-12-15T15:58:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zibotentan-astrazeneca-net-present-value/ 2024-12-15T15:57:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/briquilimab-jasper-therapeutics-net-present-value/ 2024-12-15T15:57:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aci-24-ac-immune-net-present-value/ 2024-12-15T15:57:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-112-crispr-therapeutics-net-present-value-2/ 2024-12-15T15:57:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-quadrivalent-vaccine-pfizer-net-present-value-2/ 2024-12-15T15:56:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rl-007-atai-life-sciences-net-present-value-2/ 2024-12-15T15:56:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilvegostomig-astrazeneca-net-present-value-3/ 2024-12-15T15:56:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-net-present-value-2/ 2024-12-15T15:55:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azetukalner-xenon-pharmaceuticals-net-present-value-2/ 2024-12-15T15:55:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asundexian-bayer-net-present-value-2/ 2024-12-15T15:55:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sapablursen-sodium-ionis-pharmaceuticals-net-present-value-2/ 2024-12-15T15:55:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-253-kymera-therapeutics-net-present-value-2/ 2024-12-15T15:54:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lunsekimig-sanofi-net-present-value-2/ 2024-12-15T15:54:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sns-101-sensei-biotherapeutics-net-present-value-2/ 2024-12-15T15:54:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eo-3021-elevation-oncology-net-present-value-2/ 2024-12-15T15:53:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vrdn-003-viridian-therapeutics-net-present-value-2/ 2024-12-15T15:15:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navenibart-astria-therapeutics-net-present-value-2/ 2024-12-15T15:15:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tacrolimus-tff-pharmaceuticals-net-present-value-2/ 2024-12-15T15:15:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/istisociclib-kronos-bio-net-present-value-2/ 2024-12-15T15:14:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-129-merus-net-present-value-2/ 2024-12-15T15:14:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monlunabant-novo-nordisk-net-present-value-2/ 2024-12-15T15:14:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zodasiran-arrowhead-pharmaceuticals-net-present-value-2/ 2024-12-15T15:14:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar444656-sanofi-net-present-value-2/ 2024-12-15T15:13:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naporafenibum-erasca-net-present-value-2/ 2024-12-15T15:13:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1065845-neurocrine-biosciences-net-present-value-2/ 2024-12-15T15:13:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enobosarm-veru-net-present-value-2/ 2024-12-15T15:12:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atacicept-vera-therapeutics-net-present-value-2/ 2024-12-15T15:12:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bhv-1300-biohaven-net-present-value-2/ 2024-12-15T15:12:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sys-6002-corbus-pharmaceuticals-net-present-value-2/ 2024-12-15T15:11:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-2051-cytomx-therapeutics-net-present-value-2/ 2024-12-15T15:11:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-131-crispr-therapeutics-net-present-value-2/ 2024-12-13T17:16:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fb-102-forte-biosciences-net-present-value-2/ 2024-12-13T17:16:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tn-401-tenaya-therapeutics-net-present-value-2/ 2024-12-13T17:15:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgt-003-solid-biosciences-net-present-value-2/ 2024-12-13T17:15:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epinephrine-aquestive-therapeutics-net-present-value-2/ 2024-12-13T17:15:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jzp-898-jazz-pharmaceuticals-net-present-value-2/ 2024-12-13T17:14:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iluzanebart-vigil-neuroscience-net-present-value-2/ 2024-12-13T17:14:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inb-400-in8bio-net-present-value-2/ 2024-12-13T17:14:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cln-619-cullinan-therapeutics-net-present-value-2/ 2024-12-13T17:14:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aoc-1020-avidity-biosciences-net-present-value-3/ 2024-12-13T17:13:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-19-nkarta-net-present-value-3/ 2024-12-13T17:13:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inb-100-in8bio-net-present-value-2/ 2024-12-13T17:13:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pr-006-eli-lilly-and-co-net-present-value-2/ 2024-12-13T17:12:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tc-tlr7-8-ascendis-pharma-net-present-value-2/ 2024-12-13T17:12:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribitol-bridgebio-pharma-net-present-value-2/ 2024-12-13T17:12:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elritercept-keros-therapeutics-net-present-value-2/ 2024-12-13T17:11:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pl-9643-palatin-technologies-net-present-value-2/ 2024-12-13T17:11:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdtx-1535-black-diamond-therapeutics-net-present-value-2/ 2024-12-13T17:11:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deucrictibant-immediate-release-pharvaris-net-present-value-2/ 2024-12-13T17:10:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anselamimab-astrazeneca-net-present-value-2/ 2024-12-13T17:10:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegtibatinase-travere-therapeutics-net-present-value-4/ 2024-12-13T17:10:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-jazz-pharmaceuticals-net-present-value-2/ 2024-12-13T17:09:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rgx-111-regenxbio-net-present-value-2/ 2024-12-13T17:09:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patidistrogene-bexoparvovec-sarepta-therapeutics-net-present-value-2/ 2024-12-13T17:09:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inclacumab-pfizer-net-present-value-2/ 2024-12-13T17:09:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-668-abbvie-net-present-value-2/ 2024-12-13T17:08:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrt-2359-monte-rosa-therapeutics-net-present-value-2/ 2024-12-13T17:08:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tng-908-tango-therapeutics-net-present-value-2/ 2024-12-13T17:08:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tyra-300-tyra-biosciences-net-present-value-2/ 2024-12-13T17:07:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1010-moderna-net-present-value-3/ 2024-12-13T17:07:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cft-7455-c4-therapeutics-net-present-value-3/ 2024-12-13T17:07:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-celltrion-net-present-value-2/ 2024-12-13T17:06:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-1607-nurix-therapeutics-net-present-value-3/ 2024-12-13T17:06:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cardiamp-biocardia-net-present-value-3/ 2024-12-13T17:06:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-sobis-snda-thrombocytopenia/ 2024-12-13T14:32:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-wins-vabysmo-prefilled-syringe-eu-approval-to-intensify-eylea-challenge/ 2024-12-13T11:20:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/conduit-sarborg-partner-ai/ 2024-12-13T10:51:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/a-novel-toothy-approach-to-innovating-randomization-in-clinical-trials/ 2025-02-18T12:55:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aim-covid-fatigue-therapy/ 2024-12-13T08:29:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rlyb-116-rallybio-net-present-value-2/ 2024-12-13T08:05:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oric-944-oric-pharmaceuticals-net-present-value-2/ 2024-12-13T08:04:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-net-present-value-2/ 2024-12-13T07:01:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imlunestrant-tosylate-eli-lilly-and-co-net-present-value-3/ 2024-12-13T07:00:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adi-001-adicet-bio-net-present-value-2/ 2024-12-13T07:00:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapcabtagene-autoleucel-novartis-net-present-value-3/ 2024-12-13T07:00:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/flu-vaccine-strategy-on-the-line-as-new-us-leaders-anticipated-to-take-charge/ 2024-12-12T21:44:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lemzoparlimab-i-mab-net-present-value-2/ 2024-12-13T06:59:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clesacostat-tromethamine-ervogastat-pfizer-net-present-value-2/ 2024-12-13T06:59:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inaxaplin-vertex-pharmaceuticals-net-present-value-3/ 2024-12-13T06:59:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/uliledlimab-i-mab-net-present-value-2/ 2024-12-13T06:58:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/norovirus-strains-norwalk-gi-1-sydney-gii-4-bivalent-vaccine-vaxart-net-present-value-3/ 2024-12-13T06:58:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegozafermin-89bio-net-present-value-2/ 2024-12-13T06:58:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peresolimab-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:58:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/reboxetine-axsome-therapeutics-net-present-value-2/ 2024-12-13T06:57:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aficamten-cytokinetics-net-present-value-2/ 2024-12-13T06:57:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-net-present-value-3/ 2024-12-13T06:57:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/intrachol-protara-therapeutics-net-present-value-3/ 2024-12-13T06:56:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gavorestat-applied-therapeutics-net-present-value-2/ 2024-12-13T06:56:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prx-012-prothena-corp-net-present-value-3/ 2024-12-13T06:56:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remibrutinib-novartis-net-present-value-2/ 2024-12-13T06:55:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-3927-moderna-net-present-value-3/ 2024-12-13T06:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-130-crispr-therapeutics-net-present-value-2/ 2024-12-13T06:55:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inz-701-inozyme-pharma-net-present-value-3/ 2024-12-13T06:55:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mezigdomide-bristol-myers-squibb-net-present-value-3/ 2024-12-13T06:54:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quavonlimab-merck-net-present-value-2/ 2024-12-13T06:54:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acoramidis-hydrochloride-bridgebio-pharma-net-present-value-3/ 2024-12-13T06:53:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cevaretigene-ritoparvovec-meiragtx-net-present-value-2/ 2024-12-13T06:53:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donidalorsen-sodium-ionis-pharmaceuticals-net-present-value-3/ 2024-12-13T06:53:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tld-1433-theralase-technologies-net-present-value-3/ 2024-12-13T06:52:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-net-present-value-3/ 2024-12-13T06:52:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-astrazeneca-net-present-value-4/ 2024-12-13T06:52:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vibostolimab-merck-net-present-value-3/ 2024-12-13T06:51:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1647-moderna-net-present-value-3/ 2024-12-13T06:51:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rpl-301-rocket-pharmaceuticals-net-present-value-3/ 2024-12-13T06:51:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mozafancogene-autotemcel-rocket-pharmaceuticals-net-present-value-3/ 2024-12-13T06:51:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cefepime-taniborbactam-hydrochloride-everest-medicines-net-present-value-2/ 2024-12-13T06:50:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itepekimab-sanofi-net-present-value-2/ 2024-12-13T06:50:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fhd-286-foghorn-therapeutics-net-present-value-2/ 2024-12-13T06:50:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tpst-1120-tempest-therapeutics-net-present-value-2/ 2024-12-13T06:49:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-compass-pathways-net-present-value-3/ 2024-12-13T06:49:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bbp-631-bridgebio-pharma-net-present-value-2/ 2024-12-13T06:49:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinlarebant-belite-bio-net-present-value-2/ 2024-12-13T06:48:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/casdozokitug-coherus-biosciences-net-present-value-2/ 2024-12-13T06:48:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-net-present-value-2/ 2024-12-13T06:48:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jzp-815-jazz-pharmaceuticals-net-present-value-2/ 2024-12-13T06:48:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rebisufligene-etisparvovec-ultragenyx-pharmaceutical-net-present-value-2/ 2024-12-13T06:47:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nnv1-calidi-biotherapeutics-net-present-value-2/ 2024-12-13T06:47:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/centanafadine-otsuka-net-present-value-2/ 2024-12-13T06:47:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/av-101-vistagen-therapeutics-net-present-value-2/ 2024-12-13T06:46:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tour-006-tourmaline-bio-net-present-value-2/ 2024-12-13T06:46:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3972406-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:46:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07275315-pfizer-net-present-value-2/ 2024-12-13T06:45:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nnc0519-0130-novo-nordisk-net-present-value-2/ 2024-12-13T06:45:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9574-astrazeneca-net-present-value-2/ 2024-12-13T06:45:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-1084-merck-net-present-value-2/ 2024-12-13T06:45:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-400-abbvie-net-present-value-2/ 2024-12-13T06:44:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sabestomig-astrazeneca-net-present-value/ 2024-12-13T06:44:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-441566-sanofi-net-present-value-2/ 2024-12-13T06:44:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olomorasib-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:43:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tidal-01-turnstone-biologics-net-present-value-2/ 2024-12-13T06:43:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmg-901-astrazeneca-net-present-value-2/ 2024-12-13T06:43:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-1845-novo-nordisk-net-present-value-2/ 2024-12-13T06:42:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-4604-astrazeneca-net-present-value-2/ 2024-12-13T06:42:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durcabtagene-autoleucel-novartis-net-present-value-2/ 2024-12-13T06:42:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolerogenic-dna-novo-nordisk-net-present-value-2/ 2024-12-13T06:42:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ocadusertib-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:41:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-6291-revolution-medicines-net-present-value-2/ 2024-12-13T06:41:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0780-astrazeneca-net-present-value-2/ 2024-12-13T06:41:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemacabtagene-ansegedleucel-allogene-therapeutics-net-present-value-2/ 2024-12-13T06:40:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hs-001-novo-nordisk-net-present-value-2/ 2024-12-13T06:40:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-2060-merck-net-present-value-2/ 2024-12-13T06:40:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pbft-02-passage-bio-net-present-value-2/ 2024-12-13T06:40:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pbgm-01-passage-bio-net-present-value-2/ 2024-12-13T06:39:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baxdrostat-astrazeneca-net-present-value-2/ 2024-12-13T06:39:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ucenprubart-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:39:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-net-present-value-2/ 2024-12-13T06:38:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ak-otof-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:38:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ponsegromab-pfizer-net-present-value-2/ 2024-12-13T06:38:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bexotegrast-pliant-therapeutics-net-present-value-2/ 2024-12-13T06:37:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-101-merck-net-present-value-2/ 2024-12-13T06:37:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/boserolimab-merck-net-present-value-2/ 2024-12-13T06:37:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mazdutide-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:37:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/decitabine-tetrahydrouridine-novo-nordisk-net-present-value-2/ 2024-12-13T06:36:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-383-abbvie-net-present-value-2/ 2024-12-13T06:36:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ucart-22-cellectis-net-present-value-2/ 2024-12-13T06:36:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-4830-merck-net-present-value-2/ 2024-12-13T06:35:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-8189-merck-net-present-value-2/ 2024-12-13T06:35:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ak-1780-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:35:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onfasprodil-novartis-net-present-value-2/ 2024-12-13T06:34:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efinopegdutide-merck-net-present-value-2/ 2024-12-13T06:34:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zigakibart-novartis-net-present-value-2/ 2024-12-13T06:34:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/miransertib-mesylate-merck-net-present-value-2/ 2024-12-13T06:34:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-3427-astrazeneca-net-present-value-2/ 2024-12-13T06:33:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pn-235-johnson-johnson-net-present-value-2/ 2024-12-13T06:27:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denecimig-novo-nordisk-net-present-value-2/ 2024-12-13T06:27:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insulin-icodec-semaglutide-novo-nordisk-net-present-value-2/ 2024-12-13T06:26:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nipocalimab-johnson-johnson-net-present-value-2/ 2024-12-13T06:26:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cretostimogene-grenadenorepvec-kissei-pharmaceutical-net-present-value-2/ 2024-12-13T06:26:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volenrelaxin-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:26:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvl-655-nuvalent-net-present-value-2/ 2024-12-13T06:25:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rgx-202-regenxbio-net-present-value-2/ 2024-12-13T06:25:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-net-present-value-2/ 2024-12-13T06:25:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retatrutide-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:24:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orforglipron-calcium-eli-lilly-and-co-net-present-value-2/ 2024-12-13T06:24:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ide-161-ideaya-biosciences-net-present-value-2/ 2024-12-13T06:24:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceralasertib-astrazeneca-net-present-value-2/ 2024-12-13T06:23:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-9932-novo-nordisk-net-present-value-2/ 2024-12-13T06:23:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lomedeucitinib-bristol-myers-squibb-net-present-value-2/ 2024-12-13T06:23:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lefelsiran-sodium-novo-nordisk-net-present-value-2/ 2024-12-13T06:22:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lunresertib-repare-therapeutics-net-present-value-2/ 2024-12-13T06:22:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/raludotatug-deruxtecan-daiichi-sankyo-net-present-value-2/ 2024-12-13T06:22:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlitelimab-sanofi-net-present-value-2/ 2024-12-13T06:22:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/puxitatug-samrotecan-astrazeneca-net-present-value-3/ 2024-12-13T06:21:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lonigutamab-ugodotin-acelyrin-net-present-value-2/ 2024-12-13T06:21:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/admilparant-bristol-myers-squibb-net-present-value-4/ 2024-12-13T06:21:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/palazestrant-olema-pharmaceuticals-net-present-value-2/ 2024-12-13T06:20:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/risvodetinib-inhibikase-therapeutics-net-present-value-2/ 2024-12-13T06:20:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ezobresib-bristol-myers-squibb-net-present-value-2/ 2024-12-13T06:20:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/licaminlimab-oculis-net-present-value-2/ 2024-12-13T06:20:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexmethylphenidate-hydrochloride-cingulate-net-present-value-2/ 2024-12-13T06:19:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexamethasone-acetate-oculis-net-present-value-2/ 2024-12-13T06:19:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-0101-pds-biotechnology-net-present-value-2/ 2024-12-13T06:19:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vidofludimus-calcium-immunic-net-present-value-3/ 2024-12-13T06:18:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/transcon-cnp-ascendis-pharma-net-present-value-2/ 2024-12-13T06:18:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/giroctocogene-fitelparvovec-pfizer-net-present-value-2/ 2024-12-13T06:18:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peptide-to-antagonize-grpr-for-oncology-novartis-net-present-value-2/ 2024-12-13T06:17:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazukibart-pfizer-net-present-value-2/ 2024-12-13T06:17:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cutx-101-fortress-biotech-net-present-value-2/ 2024-12-13T06:17:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sepiapterin-ptc-therapeutics-net-present-value-3/ 2024-12-13T06:01:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/suvecaltamide-hydrochloride-jazz-pharmaceuticals-net-present-value-2/ 2024-12-13T06:00:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1065846-neurocrine-biosciences-net-present-value-3/ 2024-12-13T06:00:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atrn-119-aprea-therapeutics-net-present-value-2/ 2024-12-13T06:00:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/favezelimab-merck-net-present-value-3/ 2024-12-13T05:59:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitiperstat-astrazeneca-net-present-value-3/ 2024-12-13T05:59:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vorolanib-eyepoint-pharmaceuticals-net-present-value-2/ 2024-12-13T05:59:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/petosemtamab-merus-net-present-value-2/ 2024-12-13T05:58:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linvoseltamab-regeneron-pharmaceuticals-net-present-value-3/ 2024-12-13T05:58:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/milvexian-bristol-myers-squibb-net-present-value-2/ 2024-12-13T05:58:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inupadenant-hydrochloride-iteos-therapeutics-net-present-value-2/ 2024-12-13T05:58:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-net-present-value-2/ 2024-12-13T05:57:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropivacaine-er-painreform-net-present-value-2/ 2024-12-13T05:57:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/transcon-il-2-beta-gamma-ascendis-pharma-net-present-value-2/ 2024-12-13T05:57:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kpi-012-kala-bio-net-present-value-2/ 2024-12-13T05:56:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-net-present-value-3/ 2024-12-13T05:56:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremtelectogene-empogeditemcel-vor-biopharma-net-present-value-2/ 2024-12-13T05:56:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insulin-efsitora-alfa-eli-lilly-and-co-net-present-value-2/ 2024-12-13T05:55:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tara-002-protara-therapeutics-net-present-value-3/ 2024-12-13T05:55:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ft-819-fate-therapeutics-net-present-value-2/ 2024-12-13T05:55:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lava-1207-lava-therapeutics-net-present-value-2/ 2024-12-13T05:55:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-3245-springworks-therapeutics-net-present-value-2/ 2024-12-13T05:54:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/povorcitinib-incyte-net-present-value-2/ 2024-12-13T05:54:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utreloxastat-ptc-therapeutics-net-present-value-2/ 2024-12-13T05:54:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-110-crispr-therapeutics-net-present-value-2/ 2024-12-13T05:53:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aflibercept-biosimilar-teva-pharmaceutical-industries-net-present-value-2/ 2024-12-13T05:53:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muvalaplin-eli-lilly-and-co-net-present-value-2/ 2024-12-13T05:52:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lysergic-acid-diethylamide-mind-medicine-mindmed-net-present-value-3/ 2024-12-13T05:52:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-teva-pharmaceutical-industries-net-present-value-2/ 2024-12-13T05:52:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-teva-pharmaceutical-industries-net-present-value-2/ 2024-12-13T05:51:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gefurulimab-astrazeneca-net-present-value-3/ 2024-12-13T05:51:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/medi-7352-astrazeneca-net-present-value-2/ 2024-12-13T05:51:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oleclumab-astrazeneca-net-present-value-3/ 2024-12-13T05:50:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adct-602-adc-therapeutics-net-present-value-2/ 2024-12-13T05:50:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lna-043-novartis-net-present-value-3/ 2024-12-13T05:50:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stalaris-atyr-pharma-net-present-value-3/ 2024-12-13T05:50:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sasanlimab-pfizer-net-present-value-2/ 2024-12-13T05:49:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sildenafil-citrate-dare-bioscience-net-present-value-2/ 2024-12-13T05:49:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mevidalen-hydroxybenzoate-eli-lilly-and-co-net-present-value-2/ 2024-12-13T05:49:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pelacarsen-sodium-novartis-net-present-value-3/ 2024-12-13T05:48:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pr-001-eli-lilly-and-co-net-present-value-2/ 2024-12-13T05:48:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986012-bristol-myers-squibb-net-present-value-2/ 2024-12-13T05:48:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolebrutinib-sanofi-net-present-value-2/ 2024-12-13T05:47:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axitinib-clearside-biomedical-net-present-value-2/ 2024-12-13T05:47:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sabatolimab-novartis-net-present-value-3/ 2024-12-13T05:47:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pariglasgene-brecaparvovec-ultragenyx-pharmaceutical-net-present-value-2/ 2024-12-13T05:47:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemtabrutinib-merck-net-present-value-2/ 2024-12-13T05:46:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilzabrutinib-sanofi-net-present-value-2/ 2024-12-13T05:46:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telisotuzumab-vedotin-abbvie-net-present-value-2/ 2024-12-13T05:46:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evorpacept-alx-oncology-net-present-value-3/ 2024-12-13T05:45:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pneumococcal-vaccine-cansino-biologics-net-present-value-2/ 2024-12-13T05:45:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avalotcagene-ontaparvovec-ultragenyx-pharmaceutical-net-present-value-2/ 2024-12-13T05:45:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belzupacap-sarotalocan-aura-biosciences-net-present-value-3/ 2024-12-13T05:44:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosifloxuridine-nafalbenamide-nucana-net-present-value-2/ 2024-12-13T05:44:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zenocutuzumab-merus-net-present-value-2/ 2024-12-13T03:38:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venglustat-malate-sanofi-net-present-value-2/ 2024-12-13T03:38:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esmethadone-hydrochloride-relmada-therapeutics-net-present-value-3/ 2024-12-13T03:37:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etripamil-milestone-pharmaceuticals-net-present-value-4/ 2024-12-13T03:37:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/etripamil-milestone-pharmaceuticals-net-present-value-3/ 2024-12-13T03:37:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iopofosine-i-131-cellectar-biosciences-net-present-value-3/ 2024-12-13T03:37:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linerixibat-gsk-net-present-value-3/ 2024-12-13T03:36:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sozinibercept-opthea-net-present-value-2/ 2024-12-13T03:36:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esreboxetine-axsome-therapeutics-net-present-value-2/ 2024-12-13T03:36:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onvansertib-fumarate-cardiff-oncology-net-present-value-3/ 2024-12-13T03:35:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/setanaxib-calliditas-therapeutics-net-present-value-2/ 2024-12-13T03:35:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tipifarnib-kura-oncology-net-present-value-2/ 2024-12-13T03:35:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ampligen-aim-immunotech-net-present-value-2/ 2024-12-13T03:35:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ralinepag-united-therapeutics-net-present-value-3/ 2024-12-13T03:34:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annamycin-moleculin-biotech-net-present-value-3/ 2024-12-13T03:34:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oratrope-lumos-pharma-net-present-value-3/ 2024-12-13T03:34:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zelicapavir-enanta-pharmaceuticals-net-present-value-2/ 2024-12-13T03:33:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/renizgamglogene-autogedtemcel-editas-medicine-net-present-value-2/ 2024-12-13T03:33:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/empasiprubart-argenx-net-present-value-2/ 2024-12-13T03:33:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/reolysin-oncolytics-biotech-net-present-value-2/ 2024-12-13T03:32:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lepodisiran-sodium-eli-lilly-and-co-net-present-value-2/ 2024-12-13T03:32:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tividenofusp-alfa-denali-therapeutics-net-present-value-2/ 2024-12-13T03:32:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/granite-001-gritstone-bio-net-present-value-2/ 2024-12-13T03:32:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mino-lok-citius-pharmaceuticals-net-present-value-2/ 2024-12-13T03:31:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apraglutide-ironwood-pharmaceuticals-net-present-value-2/ 2024-12-13T03:31:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-2693-astrazeneca-net-present-value-2/ 2024-12-13T03:31:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-222-gilead-sciences-net-present-value-2/ 2024-12-13T03:30:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rivunatpagene-miziparvovec-ultragenyx-pharmaceutical-net-present-value-2/ 2024-12-13T03:30:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ianalumab-novartis-net-present-value-2/ 2024-12-13T03:30:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligelizumab-novartis-net-present-value-2/ 2024-12-13T03:29:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vincerinone-ptc-therapeutics-net-present-value-3/ 2024-12-13T03:29:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monalizumab-astrazeneca-net-present-value-2/ 2024-12-13T03:29:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tyra-200-tyra-biosciences-net-present-value-2/ 2024-12-13T03:29:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/janx-007-janux-therapeutics-net-present-value-2/ 2024-12-13T03:28:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/livmoniplimab-abbvie-net-present-value-2/ 2024-12-13T03:28:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itruvone-vistagen-therapeutics-net-present-value-2/ 2024-12-13T03:22:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caba-201-cabaletta-bio-net-present-value-2/ 2024-12-13T03:22:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/decoy-20-indaptus-therapeutics-net-present-value-2/ 2024-12-13T03:21:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gtx-102-ultragenyx-pharmaceutical-net-present-value-2/ 2024-12-13T03:21:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulixacaltamide-praxis-precision-medicines-net-present-value-2/ 2024-12-13T03:21:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nalbuphine-hydrochloride-er-trevi-therapeutics-net-present-value-2/ 2024-12-13T03:21:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-3705-moderna-net-present-value-2/ 2024-12-13T03:20:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rpa-501-rocket-pharmaceuticals-net-present-value-2/ 2024-12-13T03:20:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mebufotenin-gh-research-net-present-value-2/ 2024-12-13T03:20:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ustekinumab-biosimilar-rani-therapeutics-net-present-value-2/ 2024-12-13T03:19:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/masofaniten-essa-pharma-net-present-value-2/ 2024-12-13T03:19:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imdusiran-sodium-arbutus-biopharma-net-present-value-2/ 2024-12-13T03:19:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/batoprotafib-novartis-net-present-value-3/ 2024-12-13T03:18:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/solbinsiran-sodium-eli-lilly-and-co-net-present-value-2/ 2024-12-13T03:18:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golimumab-biosimilar-teva-pharmaceutical-industries-net-present-value-2/ 2024-12-13T03:18:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-net-present-value-3/ 2024-12-13T03:18:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quilience-nls-pharmaceutics-net-present-value-2/ 2024-12-13T03:17:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemcitabine-johnson-johnson-net-present-value-3/ 2024-12-13T03:17:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maplirpacept-pfizer-net-present-value-3/ 2024-12-13T03:17:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirexatamab-leap-therapeutics-net-present-value-2/ 2024-12-13T03:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elinzanetant-bayer-net-present-value-2/ 2024-12-13T03:16:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oric-114-oric-pharmaceuticals-net-present-value-2/ 2024-12-13T03:16:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linavonkibart-scholar-rock-holding-net-present-value-2/ 2024-12-13T03:15:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibezapolstat-acurx-pharmaceuticals-net-present-value-3/ 2024-12-13T03:15:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apitegromab-scholar-rock-holding-net-present-value-3/ 2024-12-13T03:15:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tn-301-tenaya-therapeutics-net-present-value-2/ 2024-12-13T03:14:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cagrisema-novo-nordisk-net-present-value-2/ 2024-12-13T03:14:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-exelixis-net-present-value-3/ 2024-12-13T03:14:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remternetug-eli-lilly-and-co-net-present-value-2/ 2024-12-13T03:14:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venanprubart-eli-lilly-and-co-net-present-value-2/ 2024-12-13T03:13:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zorevunersen-sodium-stoke-therapeutics-net-present-value-3/ 2024-12-13T03:13:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-06835375-pfizer-net-present-value-2/ 2024-12-13T03:13:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bidridistrogene-xeboparvovec-sarepta-therapeutics-net-present-value-2/ 2024-12-13T03:12:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ecubectedin-pharma-mar-net-present-value-2/ 2024-12-13T03:12:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemircopan-astrazeneca-net-present-value-4/ 2024-12-13T03:12:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/vemircopan-astrazeneca-net-present-value-3/ 2024-12-13T03:09:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fianlimab-regeneron-pharmaceuticals-net-present-value-3/ 2024-12-13T03:08:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/doxycycline-hyclate-cr-polypid-net-present-value-2/ 2024-12-13T03:08:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalzanemdor-sage-therapeutics-net-present-value-3/ 2024-12-13T03:08:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vobramitamab-duocarmazine-macrogenics-net-present-value-2/ 2024-12-13T03:08:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olafertinib-fortress-biotech-net-present-value-2/ 2024-12-13T03:07:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sisunatovir-hydrochloride-pfizer-net-present-value-2/ 2024-12-13T03:07:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nobel-laureates-strongly-urge-senate-to-oppose-confirmation-of-rfk-jr/ 2024-12-12T17:35:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/building-up-the-infrastructure-for-future-pandemic-preparedness-frontiers-in-rapid-raw-material-production/ 2024-12-16T10:11:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-santhera-dmd-therapy/ 2024-12-12T16:03:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-indefinitely-bans-puberty-blockers-for-teenagers-due-to-unacceptable-risk/ 2024-12-12T15:26:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/meitheal-rights-cabp/ 2024-12-12T10:45:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/transforming-preventative-care-in-the-nhs/ 2024-12-12T09:18:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofis-combination-vaccines-fda/ 2024-12-12T08:38:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/activist-investor-starboards-failure-to-outmanoeuver-pfizer-management/ 2024-12-16T20:32:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ash-2024-discussions-shine-spotlight-on-advances-in-haemophilia-treatments/ 2024-12-14T01:18:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vifor-pharma-offers-23m-to-nhs-to-resolve-cma-investigation/ 2024-12-11T17:25:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/er-kim-ascendis-eurasia/ 2024-12-11T15:10:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-innovations-shoring-up-clinical-supply-chain-integrity-in-the-age-of-advanced-therapies/ 2024-12-11T13:40:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/overcoming-the-first-hurdles-navigating-early-phase-challenges-for-biotechs/ 2025-01-09T12:59:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/relation-gsk-therapy-developments/ 2024-12-11T11:17:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/better-prevention-and-treatment-options-needed-for-genital-herpes-who-says/ 2024-12-11T10:58:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/lilly-uk-life-sciences-sector/ 2024-12-11T09:53:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ash-2024-jjs-tecvayli-ndmm-patient/ 2024-12-11T09:41:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/greenberg-president-ceo-incarda/ 2024-12-11T08:19:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ash-2024-regenerons-ordspono-faces-challenges-but-positive-results-signal-hope/ 2024-12-10T19:06:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/new-amsterdam-stock-jumps-as-ldl-c-lowering-drug-scores-again-at-phase-iii/ 2024-12-10T17:02:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-chiesi-protalix-submission/ 2024-12-10T14:35:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/rsv-prophylactic-market-8mm-2030/ 2024-12-10T14:36:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/santhera-dmd-therapy-agamree-approved-for-nhs-use-after-new-price-deal/ 2024-12-10T11:13:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/seres-ser-155-breakthrough-bsis/ 2024-12-10T09:44:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-gsk-nucala-copd/ 2024-12-10T08:32:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/daiichi-sankyo-secures-breakthrough-designation-for-nsclc-treatment/ 2024-12-17T09:21:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/citryll-series-b-net/ 2024-12-09T14:51:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/reprieve-for-chinese-biotechs-as-biosecure-act-left-out-of-key-bill/ 2024-12-09T11:39:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-acquisition-catalent-ec/ 2024-12-09T11:18:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/innovative-buffer-management-solutions/ 2024-12-09T12:09:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-priority-astrazeneca-imfinzi/ 2024-12-09T08:23:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-shares-new-draft-guidance-for-accelerated-approval/ 2024-12-09T08:08:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/new-study-finds-obesity-costs-us-industry-347bn-a-year/ 2024-12-06T21:42:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/cell-gene-therapy-companies-value-proposition/ 2024-12-17T09:22:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-to-invest-3bn-in-wisconsin-facility-expansion/ 2024-12-06T14:34:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/centenarians-unlocking-the-secrets-of-living-to-100/ 2024-12-06T10:09:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/muna-gsk-alzheimers-treatments/ 2024-12-06T09:42:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-rmat-affimed-artiva/ 2024-12-09T04:15:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merus-bizengri-granted-fda-accelerated-approval-to-treat-nrg1-cancers/ 2024-12-05T16:17:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dewpoint-mitsubishi-tanabe-als/ 2024-12-05T14:13:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/leo-pharma-eczema-mhra/ 2024-12-05T10:22:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-astrazeneca-imfinzi-ls-sclc/ 2024-12-05T08:37:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ceo-of-unitedhealthcare-brian-thompson-shot-dead-in-new-york-city/ 2024-12-04T17:41:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-zepbound-wins-the-weight-loss-duel-with-novo-wegovy/ 2024-12-04T17:05:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/maze-therapeutics-lead-candidates/ 2024-12-04T14:58:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ipsen-biomunex-agreement-cancer/ 2024-12-04T09:40:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-anaemia-therapy-keros/ 2024-12-04T08:32:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/all-in-one-milling-platforms-how-to-reduce-your-machinery-footprint/ 2024-12-05T10:28:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/trump-2-0-could-see-a-rise-in-biopharmaceutical-ma-deals/ 2024-12-03T17:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/cobenfy-emraclidine-muscarinic-path/ 2024-12-03T16:18:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lundbeck-acquires-longboard-pharmaceuticals/ 2024-12-03T14:04:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-olema-alliance-250m-breast-cancer-trials/ 2024-12-03T13:17:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/turkiye-pharmaceutical-euro-exchange-rate/ 2024-12-03T12:02:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-tremfya-sblas-paediatric/ 2024-12-03T10:20:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-ptc-partner-huntingtons/ 2024-12-03T08:42:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/faron-pharma-secures-uk-innovation-passport-for-blood-cancer-immunotherapy/ 2024-12-02T17:37:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fate-bob-valamehr-ceo/ 2024-12-02T13:55:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chmp-recommends-oral-peanut-allergy-immunotherapy-treatment-for-toddlers/ 2024-12-02T11:38:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/meet-the-company-on-a-mission-to-reengineer-drug-development/ 2024-12-03T16:34:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cbc-ucb-business-china/ 2024-12-02T10:39:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uq-skin-cancer-cream/ 2024-12-02T08:07:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/interviews/prep-therapies-utter-new-hope-in-hiv-preventive-landscape-as-vaccine-failures-amass/ 2025-05-01T08:12:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-launches-esmp-for-better-management-of-drug-shortages-in-eu/ 2024-11-29T17:24:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/university-birmingham-gvhd/ 2024-11-29T14:05:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-government-to-launch-first-ever-mens-health-strategy/ 2024-11-29T12:27:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-reports-near-eradication-of-meningitis-c-amid-declining-vaccine-uptake/ 2024-11-29T11:31:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/cpis-medicines-manufacturing-innovation-centre-takes-delivery-of-pace-just-in-time-jit-clinical-trials-drug-dispensing-system/ 2024-12-06T15:59:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/allink-adc-pipeline/ 2024-12-02T14:10:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/formosa-medvisis-eye-therapy/ 2024-11-29T08:33:16+00:00 daily 0.2